Susquehanna International Group’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-36,322
| Closed | -$475K | – | 13135 |
|
|
2025
Q4 | $475K | Buy |
+36,322
| New | +$434K | ﹤0.01% | 8908 |
|
|
2025
Q3 | – | Sell |
-55,789
| Closed | -$378K | – | 12347 |
|
|
2025
Q2 | $299K | Sell |
55,789
-1,564
| -3% | -$7.58K | ﹤0.01% | 10339 |
|
|
2025
Q1 | $306K | Buy |
57,353
+20,736
| +57% | +$145K | ﹤0.01% | 10030 |
|
|
2024
Q4 | $327K | Buy |
36,617
+14,776
| +68% | +$157K | ﹤0.01% | 9633 |
|
|
2024
Q3 | $240K | Buy |
21,841
+6,347
| +41% | +$70.6K | ﹤0.01% | 10096 |
|
|
2024
Q2 | $141K | Sell |
15,494
-11,570
| -43% | -$113K | ﹤0.01% | 10760 |
|
|
2024
Q1 | $381K | Sell |
27,064
-2,291
| -8% | -$28.5K | ﹤0.01% | 9141 |
|
|
2023
Q4 | $225K | Buy |
+29,355
| New | +$162K | ﹤0.01% | 10431 |
|
|
2023
Q3 | – | Sell |
-11,291
| Closed | -$94.1K | – | 11984 |
|
|
2023
Q2 | $94.1K | Sell |
11,291
-208,021
| -95% | -$2.4M | ﹤0.01% | 10996 |
|
|
2023
Q1 | $2.92M | Buy |
219,312
+109,828
| +100% | +$1.48M | ﹤0.01% | 4385 |
|
|
2022
Q4 | $1.63M | Buy |
+109,484
| New | +$1.13M | ﹤0.01% | 5105 |
|
|
2022
Q2 | – | Sell |
-18,530
| Closed | -$83.1K | – | 12838 |
|
|
2022
Q1 | $124K | Buy |
+18,530
| New | +$110K | ﹤0.01% | 11744 |
|
|
2021
Q3 | – | Sell |
-8,379
| Closed | -$80.3K | – | 12711 |
|
|
2021
Q2 | $106K | Sell |
8,379
-12,722
| -60% | -$165K | ﹤0.01% | 12066 |
|
|
2021
Q1 | $366K | Buy |
21,101
+9,527
| +82% | +$172K | ﹤0.01% | 10183 |
|
|
2020
Q4 | $149K | Buy |
+11,574
| New | +$206K | ﹤0.01% | 10254 |
|
|
2019
Q1 | – | Sell |
-1,910
| Closed | -$50K | – | 8790 |
|
|
2018
Q4 | $50K | Buy |
+1,910
| New | +$72.3K | ﹤0.01% | 8479 |
|
|
2015
Q4 | – | Sell |
-213
| Closed | -$103K | – | 9390 |
|
|
2015
Q3 | $103K | Buy |
+213
| New | +$152K | ﹤0.01% | 9123 |
|
Susquehanna International Group's ATXS Position: Q1 2026 in Review
Susquehanna International Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 36,322 shares — an estimated $475K sold.
Susquehanna International Group first reported a position in ATXS in Q3 2015 and held it in 17 quarters. The position peaked at $2.92M in Q1 2023. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Susquehanna International Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 36,322 Astria Therapeutics shares in Q1 2026, an estimated $475K.
- Susquehanna International Group first reported a position in Astria Therapeutics in Q3 2015 and held it in 17 quarters.
- Susquehanna International Group's Astria Therapeutics position peaked at $2.92M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.